Specialist drug discovery company Immupharma (IMM:AIM) announced a licence and development agreement with US firm Avion Pharmaceuticals LLC for the exclusive rights to its Lupus drug Lupizor in the US, putting a rocket under the shares which have more than trebled this morning to 22.2p from 7.1p last night.A trademark license agreement has also been signed which gives Avion the right to...

The shares of 27 AIM companies have doubled or better so far in 2018. For those that don't know, AIM is the Alternative Investment Market, the junior trading platform of the stock market designed to nurture small, growth companies.While the rewards can be substantial, so are the risks, a point illustrated by Bahamas Petroleum (BPC:AIM) today. Its stock tanked more than 60% on Friday 24 August...

Shares in biopharma firm Faron Pharmaceuticals (FARN:AIM) have plummeted over 80% to 126p after its Phase III trial for its Traumakine treatment failed.Faron says Traumakine did not result in an 'increased number of ventilator-free survival days or a reduced mortality rate' when compared to a placebo. The shocking clinical trial failure flags the huge risks that small pharma companies face...

Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on 17 April showing how risky early stage drug development really is.The company's lead drug Lupuzor failed to show meaningful statistical benefits over a placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez.ImmuPharma's share price crashed...

Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez.This massive blow has...

There is welcome positive news for retail investors on Tuesday after largely upbeat trading updates from Associated British Foods (ABF) and JD Sports Fashion (JD.) lift an otherwise gloomy sector backcloth.AB Foods jumps to the top of the FTSE 100 leader board in early trade, up 4% to £26.88, after reporting a resilient retail performance from its discount chain Primark. The figures show a 1%...

By the Shares teamInvestors are spoiled for choice when it comes to small cap stocks with exciting events. As a taster for what's to come in 2018, we've scoured the markets to look for some of the most interesting activities.Read on to discover 19 stocks either expecting big news in the very near future or ones which are in the middle of developments which could have a big impact on their...

It has been a volatile few years for the healthcare industry with several headwinds acting as a drag on performance, including the threat of drug pricing caps and healthcare reform in the US. Is life now getting better?The NASDAQ Biotech index in early October traded at its highest level since December 2015. On the UK stock market, shares in many drug makers have been in a rising trend since...

Fancy doubling your money in a year by investing in an exciting stock? Sounds great, doesn't it? It's harder than you think, but certainly not impossible.Over the past 12 months, robotic process automation specialist Blue Prism (PRSM:AIM) is up by 439%; online musical equipment retailer Gear4Music (GFM:AIM) has increased by 341%; and computer games service group Keywords Studios (KWS:AIM) is...

Lupus was recently thrust into the spotlight after singer Selena Gomez cancelled her world tour to deal with the autoimmune chronic inflammatory disease, which currently has no cure.Drug developer ImmuPharma (IMM:AIM) has a pivotal year ahead as it undergoes its Phase III trial for its lead treatment Lupuzor to help treat lupus. The drug has been tipped to have blockbuster status.Management...

Addiction treatment specialist Indivior's (INDV) shares marched almost 20% higher to 359.6p on 17 August 2016 thanks to news about a phase III clinical trial.The late stage tests appear to prove the £2.3 billion cap's opioid addiction treatment works, moving it closer to market approval and $500 million of potential sales by 2020, according to stockbroker Numis.The market's very positive...

Fevertree goes for the doubleAnalysts have once again upgraded earnings forecasts for Fevertree Drinks (FEVR) following another bullish trading update. Investec lifts its 2016 pre-tax profit estimate by 9% to £26.5 million. That is essentially twice the amount it originally forecast Fevertree to make this year (£13.9 million) when initiating coverage on the stock in January 2015....

Commodity price gains from copper to corn help the FTSE 100 kick off on the front foot as the blue chip index moves close to erasing losses in the week-to-date.London's leading stocks gain 0.9% to 6,241 with oil stocks leading the way.Brent and West Texas Intermediate, key benchmarks for crude oil, are trading slightly higher at $50.12 (£34.74) and $49.20, respectively.Natural gas, gold,...

UK stocks continue their shortened week slide in early trade on Wednesday as investors wade through a plethora of corporate announcements, with miners and supermarkets acting as a particular drag on blue-chips. The FTSE 100 index falls nearly 40 points, or about 0.6%, to 6,148, matching declines on Wall Street and Asian markets overnight, and across major European indices.Supermarket...

Five directors of drug developer ImmuPharma (IMM:AIM) have invested their own money as part of a wider £8.3 million fundraise to support clinical trials of its Lupuzor drug which aims to treat life threatening auto immune disease Lupus.The chief executive, chairman, chief science officer (CSO) and two non-executive directors have agreed to buy a combined £355,000 worth of shares at 26p. The...

Drug developer ImmuPharma (IMM:AIM) dives 12% to 25.5p on Friday morning after outlining plans to raise at least £7.5 million in a heavily discountedplacing.The company, which specialises in finding treatments for serious medical conditions, such as autoimmune diseases, intends to sell a minimum of 11.8 million shares through a placing at 26p each.These shares will be sold for 10.3% lower...

London shares made decent gains in early trade on Wednesday, buoyed by positive economic news from China and a smattering of upbeat corporate statements. The FTSE 100 index rallies 55 points, or about 0.8%, to 6,436, echoing a positive showing for US markets overnight.Heading the Footsie leader board is metal and mining group Glencore (GLEN), its' shares surging 4.7% to 125.1p thanks to...

UK shares are largely flat despite a swathe of corporate announcements on Monday. The FTSE 100 slips a barely noticeable 10 points lower to 6,570, although midcaps again suffer more harsh treatment from investors. The FTSE 250 index slumps more than 1090 points, or 0.6%, to 17,392.Theme park operator Merlin Entertainments (MERL) tumbles 4.6% to 403.8p after warning the high profile...

London markets barely move in early trading on Thursday as investors pay a cautious hand ahead of today's important European Central Bank (ECB) statement. Experts predict a new swathe of money printing will be unveiled by the ECB, perhaps worth up to €1 trillion, is another desperate attempt to halt eurozone stagflation and spark growth.The FTSE 100 nudges just over 0.1% higher to 6,736,...

Eagle Eye (EYE:AIM) 165pAIM is littered with strugglers chasing the mobile commerce dream but Eagle Eye is off to a decent start. SMS marketing and vouchers space has potential, but this is also high-risk territory.Earthport (EPO:AIM) 45.25pNew management is key to ending years of failure and cash calls. Making rapid progress to promised global platform for medium-sized cross-border payments...